Lexeo Therapeutics (LXEO) director Laura Sepp-Lorenzino files Form 3

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. director Laura Sepp-Lorenzino has filed a Form 3 insider ownership report. The provided data lists her status as a director of the company and shows no reported transactions, share holdings, or derivative securities in this filing excerpt.

Key Terms

Form 3, reporting person, derivative securities

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): structured insider report header"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"The reporting person is listed as Laura Sepp-Lorenzino, a director."

derivative securities financial

"The derivativeSummary field is empty, indicating no derivative securities listed."

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sepp-Lorenzino Laura

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/28/2026

3. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Youjin Choi, Attorney-in-Fact	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Lexeo Therapeutics (LXEO) disclose in this Form 3?

The Form 3 data shows that Laura Sepp-Lorenzino is a director of Lexeo Therapeutics, Inc.. The excerpt lists no share transactions, holdings, or derivative securities associated with her in this specific filing data.

Who is the reporting person in Lexeo Therapeutics (LXEO) latest Form 3?

The reporting person is Laura Sepp-Lorenzino, identified as a director of Lexeo Therapeutics, Inc.. She is not listed as an officer or ten percent owner in the structured Form 3 data provided.

Are any share transactions reported for LXEO director Laura Sepp-Lorenzino?

No transactions are reported in this Form 3 data for Laura Sepp-Lorenzino. The transaction summary shows zero buys, zero sells, zero derivative exercises, and no gifts or tax-withholding entries in the current excerpt.

Does the Lexeo Therapeutics (LXEO) Form 3 show derivative securities?

The provided Form 3 data shows an empty derivativeSummary, indicating no derivative securities listed for Laura Sepp-Lorenzino in this excerpt. The transaction summary also reports zero derivative transactions overall.

What ownership role is indicated for Laura Sepp-Lorenzino at Lexeo Therapeutics (LXEO)?

The Form 3 data marks Laura Sepp-Lorenzino as a director of Lexeo Therapeutics, Inc.. She is not flagged as an officer or as a ten percent owner in the structured information provided here.